- Home
- CNTA vs CPRX Comparison
CNTA vs CPRX Comparison
Compare CNTA & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | CPRX |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CNTA | CPRX |
|---|---|---|
| Price | $26.92 | $22.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $40.89 | $35.00 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 03-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | N/A | $8.00 |
| Revenue Next Year | N/A | $9.77 |
| P/E Ratio | ★ N/A | $13.28 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $9.60 | $19.05 |
| 52 Week High | $30.58 | $26.56 |
Technical Indicators
Market Signals| Indicator | CNTA | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 38.69 |
| Support Level | $24.62 | $22.25 |
| Resistance Level | $27.56 | $24.94 |
| Average True Range (ATR) | 1.37 | 0.69 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 43.26 | 12.84 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.